AUG 31, 2021 7:00 AM PDT

Convalescent Plasma Therapy for COVID-19 Doesn't Work

WRITTEN BY: Tara Fernandes

After encountering an infectious agent, the immune system begins churning out antibodies—Y-shaped warriors that neutralize pathogens—into the blood circulation. In theory, donor blood from patients who have recovered from an infection could be used therapeutically, helping those experiencing severe symptoms recover.

In the case of COVID-19, the U.S. Food and Drug Administration (FDA) granted emergency authorization for convalescent plasma therapy earlier on in the pandemic. This therapy was targeted towards patients in hospitals suffering from COVID-19, particularly those who were immunocompromised. Since its authorization, tens of thousands of patients in the U.S. have been administered convalescent plasma therapy, despite the lack of clinical trial data to support the efficacy of the treatment.

Now, a recent study by Stanford researchers has revealed the harsh reality of convalescent plasma therapy for COVID-19: it doesn’t work.

A clinical trial called C3P0 was initiated by researchers at the National Institutes of Health around a year ago. The study aimed to understand how high-risk patients (such as those with underlying medical conditions such as asthma and Type 2 diabetes) would benefit from convalescent plasma therapy at the early stages of COVID-19 infection. This subset of patients is especially prone to progressing on to more severe, life-threatening symptoms of the disease, and early on during the pandemic, there were very few clinical options to support their recovery.

In February—despite only enrolling around 500 of the targeted 900 study participants—the C3PO study was terminated after researchers found no benefit of convalescent plasma at resisting severe COVID-19 symptoms compared to the placebo. 

Initially, researchers involved in the study estimated that plasma therapy might slash the risk of COVID-19 progression by around 10 percent. However, the clinical data collected from C3PO revealed that this number was under two percent.

“While this trial was negative, we need to continue this research to understand when passive immunotherapy such as convalescent plasma can be effective in treating emerging infectious diseases,” commented Kevin Schulman, one of the lead investigators involved in this work.

 

Source: The New England Journal of Medicine, Stanford Medicine.


 

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
JUL 01, 2022
Coronavirus
Nanobodies Could Protect Us From Every Variant
JUL 01, 2022
Nanobodies Could Protect Us From Every Variant
Immune reactive molecules called nanobodies, which are based on molecules found in llamas could offer robust protection ...
JUL 05, 2022
Immunology
A New Type of Universal Flu Vaccine
JUL 05, 2022
A New Type of Universal Flu Vaccine
Researchers have created a new 'universal' flu vaccine, which is directed against type A influenza viruses. It w ...
JUL 19, 2022
Clinical & Molecular DX
As Rates of Thyroid Cancer Continue to Increase, Researchers Question Why
JUL 19, 2022
As Rates of Thyroid Cancer Continue to Increase, Researchers Question Why
Beginning in the early 1990’s, rates of thyroid cancer began to drastically increase. Though this trend has contin ...
JUL 16, 2022
Microbiology
Breastmilk Can Reduce Infection Risk, with a Tradeoff
JUL 16, 2022
Breastmilk Can Reduce Infection Risk, with a Tradeoff
Breastfeeding is encouraged because it provides many benefits to both mothers and infants. Breastmilk is nutritious, and ...
SEP 21, 2022
Immunology
Calorie Reduction Lowers Levels of Aging-Linked Proteins
SEP 21, 2022
Calorie Reduction Lowers Levels of Aging-Linked Proteins
A variety of studies have suggested that diets that restrict or reduce caloric intake can lengthen lifespan. Now, resear ...
SEP 26, 2022
Drug Discovery & Development
Respiratory Syncytial Virus Antigens and Antibodies
SEP 26, 2022
Respiratory Syncytial Virus Antigens and Antibodies
In early April, Pfizer announced a $525 million acquisition of ReViral’s novel therapy for respiratory syncytial v ...
Loading Comments...